LawPlayer
My bookmarksSign up freeSign up free
Source

Commission Implementing Regulation (EU) 2016/1085 of 5 July 2016 approving Bacillus amyloliquefaciens strain ISB06 as an existing active substance for use in biocidal products of product-type 3 (Text with EEA relevance)

Commission Implementing Regulation (EU) 2016/1085 of 5 July 2016 approving Bacillus amyloliquefaciens strain ISB06 as an existing active substance for use in biocidal products of product-type 3 (Text with EEA relevance)

Implementing Regulation (EU) 2016/1085 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Bacillus amyloliquefaciens strain ISB06 is approved as an active substance for use in biocidal products of product-type 3, subject to the conditions set out in the Annex.

Article 2

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Common Name IUPAC Name Identification Numbers Minimum degree of purity of the active substance  ( 1 ) Date of approval Expiry date of approval Product type Specific conditions Bacillus amyloliquefaciens strain ISB06 Not applicable No relevant impurities 1 January 2018 31 December 2027 3 The authorisations of biocidal products are subject to the following conditions: 1. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. 2. In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users. ( 1 )   The purity indicated in this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active substance.

Other acts of the same type
Commission Implementing Regulation (EU) 2024/355 of 23 January 2024 amending Implementing Regulation (EU) 2021/2266 as regards the reference to the certificate for independent small producers of alcoholic beverages and the self-certification by those producers in the administrative documentsCommission Implementing Regulation (EU) 2024/357 of 23 January 2024 imposing a definitive anti-dumping duty on imports of certain open mesh fabrics of glass fibres originating in the People’s Republic of China as extended to imports consigned from India, Indonesia, Malaysia, Taiwan and Thailand following an expiry review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and the CouncilCommission Delegated Regulation (EU) 2024/369 of 23 January 2024 supplementing Directive (EU) 2020/2184 of the European Parliament and of the Council by laying down the procedure regarding inclusion in or removal from the European positive lists of starting substances, compositions and constituentsCommission Delegated Regulation (EU) 2024/370 of 23 January 2024 supplementing Directive (EU) 2020/2184 of the European Parliament and of the Council by laying down conformity assessment procedures for products that come into contact with water intended for human consumption and the rules for the designation of conformity assessment bodies involved in those proceduresCommission Delegated Regulation (EU) 2024/371 of 23 January 2024 supplementing Directive (EU) 2020/2184 of the European Parliament and of the Council by establishing harmonised specifications for the marking of products that come into contact with water intended for human consumptionCommission Regulation (EU) 2024/341 of 22 January 2024 amending Annexes II and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for diethofencarb, fenoxycarb, flutriafol and pencycuron in or on certain productsCommission Regulation (EU) 2024/342 of 22 January 2024 amending Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for cyflumetofen, oxathiapiprolin and pyraclostrobin in or on certain productsCommission Regulation (EU) 2024/344 of 22 January 2024 amending and correcting Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for mandipropamid in or on certain productsCommission Regulation (EU) 2024/345 of 22 January 2024 amending Annexes II, III and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for desmedipham, etridiazole, flurtamone, profoxydim, difenacoum and potassium permanganate in or on certain productsCommission Regulation (EU) 2024/346 of 22 January 2024 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council and the Annex to Commission Regulation (EU) No 231/2012 as regards the use of trimagnesium dicitrate in food supplementsCommission Regulation (EU) 2024/347 of 22 January 2024 amending Annexes II and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for fipronil in or on certain productsCommission Regulation (EU) 2024/352 of 22 January 2024 amending Annexes II and V to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for (Z)-13-hexadecen-11-yn-1-yl acetate, (Z,Z,Z,Z)-7,13,16,19-docosatetraen-1-yl isobutyrate, acrinathrin, azimsulfuron, famoxadone, prochloraz and sodium hypochlorite in or on certain products

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next